Merck halts enrollment of two Keytruda trials in MM

Merck & Co. Inc. (NYSE:MRK) said it halted enrollment of two trials of Keytruda pembrolizumab to treat multiple myeloma in order to "better understand more reports of death" in the studies' Keytruda arms.

On a recommendation from an external DMC, the pharma said it will suspend enrollment in the Phase III KEYNOTE-183 and KEYNOTE-185 trials. Spokesperson Pamela Eisele declined to provide further details...